Skip to main content
Molecular Therapy. Nucleic Acids logoLink to Molecular Therapy. Nucleic Acids
. 2024 Apr 18;35(2):102189. doi: 10.1016/j.omtn.2024.102189

Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model

Vanessa Zancanella, Astrid Vallès, Jolanda MP Liefhebber, Lieke Paerels, Carlos Vendrell Tornero, Hendrina Wattimury, Tom van der Zon, Kristel van Rooijen, Monika Golinska, Tamar Grevelink, Erich Ehlert, Elsbet Jantine Pieterman, Nanda Keijzer, Hans Marinus Gerardus Princen, Geurt Stokman, Ying Poi Liu
PMCID: PMC11046998  PMID: 38681817

Main text

(Molecular Therapy: Nucleic Acids 32, 454–467; June 2023)

In the originally published version of this article, Table 2 was found to contain two minor errors: (1) one data point was accidentally duplicated, and (2) for one data point a decimal is missing. For the Moderate-high dose rAAV5-miAngE + statin group, the correct value for mean (SD) ALT activity, week 16, should read 155.7 ± 165.2 (instead of 355.8 ± 366.2). For the rAAV5-miSCR group, the correct value for mean (SD) AST activity, week 12, should read 144.0 ± 30.3 (i.e., including decimal “0”).

These errors have been corrected in the article online, and the authors apologize for any confusion this may have caused.


Articles from Molecular Therapy. Nucleic Acids are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES